Gilead Sciences's (GILD) Biktarvy Demonstrate Consistent Efficacy Profile in Real-World Setting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- European shares subdued as surging crude sharpens focus on ECB rate path
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) Beats as Expected - Morgan Stanley
October 29, 2021 7:26 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $84.00 price target on Gilead Sciences (NASDAQ: GILD) after 3Q revenue beat consensus by 19% ($7,421M vs. $6,237M) and EPS beat by 53% ($2.65 vs. $1.73). Upside was driven by Veklury (+$1,276M) and lower costs while 2021 revenue and EPS... More
Gilead Sciences (GILD) PT Lowered to $71 at BofA Securities
October 29, 2021 5:40 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on Gilead Sciences (NASDAQ: GILD) to $71.00 (from $73.00) while maintaining a Neutral rating.... More
Gilead trims 2021 sales forecast for non-COVID products
October 28, 2021 4:22 PM EDTBy Deena Beasley
(Reuters) -Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.
Without Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.
Gilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare... More
Gilead Sciences (GILD) Tops Q3 EPS by 94c
October 28, 2021 4:04 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.65, $0.94 better than the analyst estimate of $1.71. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.18 billion.
GUIDANCE:
Gilead Sciences sees FY2021 EPS of $7.90-$8.10, versus the consensus of... More
